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Medical Sciences. In the article ‘‘The leukemic core binding
factor b-smooth muscle myosin heavy chain (CBFb–SMMHC)
chimeric protein requires both CBFb and myosin heavy chain
domains for transformation of NIH 3T3 cells’’ by Amitav
Hajra, Pu P. Liu, QingWang, Christine A. Kelley, Terryl Stacy,
Robert S. Adelstein, Nancy A. Speck, and Francis S. Collins,
which appeared in number 6, March 14, 1995, of Proc. Natl.
Acad. Sci. USA (92, 1926–1930), the authors request that the
following be noted. ‘‘Recent information has come to light that
experiments reported in this paper can in several instances not
be verified as correct. The critical experiments are being
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myosin heavy chain domains for transformation of NIH 3T3 cells
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ABSTRACT An inversion of chromosome 16 associated
with the M4Eo subtype of acute myeloid leukemia produces a
chimeric protein fusing the f3 subunit of the transcription
factor core binding factor (CBFf8) to the tail region of smooth
muscle myosin heavy chain (SMMHC). We investigated the
oncogenic properties of this CBFI-SMMHC chimeric protein
using a 3T3 transformation assay. NIH 3T3 cells expressing
CBFI-SMMHC acquired a transformed phenotype, as indi-
cated by their ability to form foci, grow in soft agarose, and
form tumors in nude mice. Cells expressing normal CBFj3 or
the SMMHC tail domain did not become transformed. Elec-
trophoretic mobility-shift assays showed that extracts from
cells transformed by CBFI-SMMHC no longer formed the
normal CBF/DNA complex but instead formed a much larger
complex that did not migrate into the gel. Analysis of CBFP-
SMMHC deletion mutants demonstrated that the chimeric
protein was transforming only if two domains were both
present: (i) CBF,B sequences necessary for association with the
CBFca subunit, and (ii) SMMHC sequences important for the
formation of multimeric filaments. These results are direct
evidence that CBF,B-SMMHC can function as an oncoprotein.
A characteristic pericentric inversion of chromosome 16
[inv(16)(pl3q22)] is present in virtually all cases of the M4Eo
subtype of acute myeloid leukemia (1, 2). We have recently
shown (3) that this inversion produces a chimeric protein in
which the tail region of smooth muscle myosin heavy chain
(SMMHC) is fused in-frame to the end of the 13 subunit of core
binding factor (CBF).
CBF (also known as PEBP2) was first identified as a murine
transcription factor that binds to viral enhancers at the se-
quence RACCRCA (where R represents a purine) (4,5). CBF
has subsequently been shown to regulate the transcription of
T-cell- (6) and myeloid-specific genes (7) and cooperate with
the transcription factors Ets-1 and c-Myb in DNA binding and
transcriptional activation (8, 9). CBF consists of two subunits:
a DNA-binding a subunit and a 1 subunit that does not bind
DNA directly but stabilizes DNA binding by CBFa. Three
different CBFa subunits have been identified (10-12), and one
of them (AML1) is disrupted by leukemia-associated t(8;21)
and t(3;21) translocations (13-16, 32). CBF13, in contrast, is
encoded by a single, ubiquitously expressed gene (17, 18). The
inv(16) rearrangement fuses all but the last 22 amino acids of
CBF13 to SMMHC (3).
SMMHC (19) is a member of the myosin II class of proteins.
It forms two of the subunits of hexameric smooth muscle
myosin and consists of an amino-terminal globular domain that
binds actin and has ATPase activity as well as a tail region that
dimerizes to form a long rod of a-helical coiled-coil structure.
The tail region becomes fused in-frame to CBFP3 as a result of
inv(16) (3).
We are interested in studying how CBF,B-SMMHC func-
tions in oncogenesis. Transformation assays using 3T3 cells
have been previously used to investigate the properties of
leukemia-associated oncogenes (20, 21). In addition, 3T3 cells
express functional CBF, and CBF/DNA complexes are altered
in 3T3 cells transformed by Ha-ras (10, 11, 18, 22). Therefore,
we reasoned that a 3T3 transformation assay would be useful
to analyze the oncogenic properties of CBF3-SMMHC.
MATERIALS AND METHODS
Generation of Antibodies. An affinity-purified polyclonal
antibody (designated GPPP) specific for the 200-kDa isoform
of SMMHC was generated against a synthetic peptide corre-
sponding to the carboxyl-terminal nine amino acids (GPP-
PQETSQ) of human umbilical artery SMMHC200 (19) by using
described methods (23). Monoclonal antibodies 1313 and ,314
were raised against bacterially expressed CBF,B by using NS-1
myeloma cells according to standard procedures (24). The
antibody isotypes were IgGl (1313) and IgG2a (1314), and
immunoblot analysis of CBFf3 deletion proteins indicated that
the antibodies recognized epitopes between amino acids 26
and 55 (1313) and 141 and 165 (1314) (data not shown).
Generation and Characterization of Stably Transfected Cell
Lines. Full-length cDNAs encoding human CBF13 and CBF13-
SMMHC (25) were cloned into the mammalian expression
vector pRc/CMV (Invitrogen). 3T3 cells were transfected with
these plasmids by calcium phosphate coprecipitation and
grown as described (26). Colonies resistant to G418 sulfate
(Geneticin, GIBCO/BRL) were isolated and expanded to
generate stably transfected cell lines.
Expression of recombinant proteins was determined by
immunoblotting with standard procedures (24). For detection
of CBF,B, cell extracts were first immunoprecipitated with
antibody 1313 and protein G (Pharmacia) before gel electro-
phoresis. Blotted proteins were detected with either GPPP
(diluted 1:10,000) or P14 (diluted 1:200) antibodies using the
Lumi-GLO chemiluminescent immunoblot kit (Kirkegaard &
Perry Laboratories). Nuclear extractions and electrophoretic
mobility-shift assays (EMSAs) were done as described (25,33).
The doubling times and saturation densities of the cells were
measured as described (20). Assessment of foci formation,
growth in 0.6% soft agarose, and in vivo tumor formation in
nude mice were done as described (20, 21).
Construction and Characterization of Deletion Mutants.
Truncated derivatives of murine CBF13 prepared by PCR
Abbreviations: CBF, core binding factor; EMSA, electrophoretic
mobility-shift assay; GST, glutathione-S-transferase; SMMHC,
smooth muscle myosin heavy chain.
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FIG. 1. Expression of CBF,B and CBF3SSMMHC proteins in
clonal, stably transfected cell lines. The predicted sizes of the CBF,3
and CBF-SSMMHC proteins are 21.5 and 67 kDa, respectively. (A)
Immunoblot of cell extracts probed with antibody GPPP. The first lane
contains an extract from cells expressing CBFj, and six representative
CBF3-SMMHC cell lines are shown. The positions of molecular mass
standards (in kDa) are shown at left. (B) Immunoblot of cell extracts
immunoprecipitated and probed with anti-CBF,B monoclonal antibod-
ies. Extracts from five different CBFf3 cell lines are shown, as well as
extracts from cell lines expressing CBF3-SMMHC (C/M) or vector
sequences alone (V). Arrows at left indicate positions of the CBFI3 and
CBF,-BSMMHC proteins, and the positions of molecular mass stan-
dards (in kDa) are indicated at right.
amplification were cloned into the glutathione-S-transferase
(GST) fusion vector pGEX2T (Pharmacia) and expressed in
bacteria and purified as described (17). EMSAs were done by
mixing the CBFP3 proteins with purified bovine CBFa and
incubating with a probe containing a high-affinity CBF-
binding site as described (17). One and one-half micrograms
of CBFJ3 protein was used for the binding reactions, so that it
was present in great excess over CBFa.
CBFfI-SMMHC deletion mutants were constructed by PCR
amplification of the appropriate cDNA regions using Pfu
polymerase (Stratagene) and primers slightly altered to intro-
duce the appropriate truncation/fusion sequence. After the
PCR product was cloned into the full-length cDNA, regions
amplified by PCR were sequenced to confirm the presence of
the correct sequence. Cells expressing the mutants were
characterized as described above, except that in vivo tumori-
genicity assays in nude mice were not done.
Determination of Myosin Solubility Curves. Protein solu-
bility curves were determined by using a variation of a de-
scribed procedure (27). Briefly, stably transfected cells were
lysed in various concentrations of KCl, and lysates were treated
with DNase (Sigma) and centrifuged at 500 x g for 10 min at
4°C. The amount of recombinant protein present in the
supernatant and pellet at each KCl concentration was deter-
mined by ELISA with the appropriate antibody. Horseradish
peroxidase-labeled goat anti-rabbit IgG (for antibody GPPP)
or anti-mouse IgG (for 1313/1314) antibodies (Kirkegaard &
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FIG. 2. (A) Foci formation by representative cells stably expressing
insertless vector, normal CBFI, or CBFI-SMMHC. (B) EMSA of
nuclear extracts from representative NIH 3T3 cells stably expressing
vector alone, CBFf3, or CBFfSMMHC (C/M) incubated with a
probe containing a high-affinity CBF-binding site. comp., Competitor
probe added to binding reaction. Binding reactions were done either
without additional unlabeled competitor (-) or in the presence of a
200-molar excess of unlabeled probes containing high-affinity (HA) or
mutated (M) CBF-binding sites.
Perry Laboratories) were used as secondary antibodies, and
immunoreactive products were detected as described (24).
RESULTS
Analysis of Transfected Cells. Stably transfected, clonal cell
lines expressed the appropriate recombinant proteins at high
levels. As shown in Fig. 1A, the GPPP antibody detected
CBFI3-SMMHC with high specificity in extracts from stably
transfected cells. The anti-CBFP3 monoclonal antibodies could
also detect C-BFP-SMMHC as well as recombinant human
CBFI3 in transfected cells and also the endogenous murine
CBF,B (Fig. 1B). A CBF,B protein doublet was often seen in
both transfected and untransfected cells.
CBF3-SMMHC-expressing cells had a more rounded, re-
fractile morphology than CBF,B-expressing cells, which had the
same morphology as untransfected cells (data not shown).
CBF,B-SMMHC cell lines grew more slowly than CBF/3 cell
lines but had a higher saturation density (Table 1). Phenotypic
characterization of the cells demonstrated that CBFf3-
SMMHC cell lines acquired a transformed phenotype, as
indicated by their ability to form foci, grow in 0.6% soft
agarose, and form tumors when injected into nude mice (Table
1 and Fig. 2A). Cells expressing normal CBFP3 or insertless
vector retained a normal phenotype (Table 1 and Fig. 2A). As
shown in Fig. 2B, extracts from cells expressing CBFI3 formed
the CBF/DNA complex normally seen in 3T3 cells (5), but
extracts from cells expressing CBF,B-SMMHC formed a much
larger complex that barely migrated into the gel.
Table 1. Characteristics of clonal, stably transfected NIH 3T3 cell lines
Saturation Soft agar Tumors in nude mice,
Cell line Doubling time, density, Foci, no. per colonies, no. per no. of
expression hr cells x 10-6 1000 cells no. per 1000 cells injection sites
Vector alone 24.0 ± 0.4 3.2 ± 0.2 8.4 ± 1.1 0.0 ± 0.0 0/2
CBF,B 24.0 ± 0.6 3.3 ± 0.3 9.4 ± 1.0 0.0 ± 0.0 0/10
CBF,B-SMMHC 40.0 ± 0.8 6.3 ± 0.2 620.1 ± 27.3 61.3 ± 7.7 12/12
Representative cell lines expressing vector only (cell line RC-1), CBF,B (cell line C182-2), and CBF3-SMMHC (C/M-5) are
shown. Values for doubling times, saturation densities, and numbers of foci and soft agar colonies are means ± SEMs from five
separate experiments. The number of tumors in nude mice are total numbers from all experiments (two injection sites per mouse).
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Characteristics of Cell Lines Expressing CBFI-SMMHC
Deletion Mutants. Fig. 3 schematically shows the deletion
mutants constructed to identify regions of CBF,B-SMMHC
important for 3T3 transformation. First, we made constructs
with only the CBF/3 or SMMHC portions of CBF,B-SMMHC
(C165, MHCR). We also constructed mutants with deletions
in CBFj3 sequences (CAC24/M, CAC32/M, CAC78/M,
CAex3/M, CAN11/M). Another group of mutants (C/
MAC68, C/MAC158) had deletions of the SMMHC carboxyl
terminus, which has been shown to be necessary for formation
of multimeric myosin filaments (28, 29). In addition, a mutant
(C/MA1182) was constructed with an internal SMMHC dele-
tion predicted to have no effect on multimerization (28). The
first two columns of Fig. 3 summarize the ability of these
mutants to associate with CBFa in DNA-binding assays and
self-associate to form multimers (see below).
We established at least four stably transfected, clonal cell
lines for each mutant construct. Proteins of the appropriate
size, as predicted from the amino acid sequence, were detected
in all the cell lines by immunoblotting (data not shown). The
phenotypes of these cell lines are summarized in the last
column of Fig. 3. Cells expressing CAC24/M and C/MAI182
had transformed phenotypes and formed approximately the
same numbers of foci ('600) and soft agarose colonies (-65)
as cells expressing CBFf-SMMHC. Cells expressing the
CAC32/M construct appeared to have an attenuated trans-
formed phenotype; while the cells formed the same number of
foci and soft agarose colonies as other transformed cells, these
foci and colonies were distinctly smaller (data not shown).
Cells expressing all other deletion mutants retained a non-
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FIG. 3. Schematic drawing of mutants with deletions of various
regions of CBF3-SMMHC. Full-length -CBFf-SMMHC (C/M) and
CBFf3 (C182) proteins are also shown for comparison. The white boxes
represent CBFl3 sequences, whereas black boxes represent SMMHC
sequences. Numbers above boxes are the amino acid locations of the
indicated boundaries, and lines under the boxes show which regions
become fused together in the deletion mutants. The CAex3/M and
CAC32/M constructs represent alternatively spliced isoforms of CBFB
lacking exons 3 and 5, respectively (17, 18). Columns to the right of the
boxes summarize whether the deletion mutants can (+) or cannot (-)
associate with CBFa (Figs. 4A and B) and form multimers (Fig. 4C).
The +/- in the first column indicates that CAC32/M associates
weakly with CBFa. The last column summarizes whether cells ex-
pressing the constructs have a transformed (T, t) or nontransformed
(N) phenotype. Transformed cells formed approximately the same
number of foci and soft agarose colonies as CBF3-SMMHC-express-
ing cells, whereas nontransformed cells formed very few foci and no
soft agarose colonies, like CBFI3-expressing cells. t, CAC32/M cells
formed smaller foci and soft agarose colonies than other transformed
cells (data not shown).
Ability of Deletion Mutants to Associate with CBFc. The
ability of bacterially expressed, truncated CBF,B proteins to
associate with purified CBFa is shown in Fig. 4A. Although
CBFa could form a complex with DNA by itself (a arrow), it
formed a larger complex when associated with the CBF3/GST
proteins (a + f3 arrow). As previously shown (18), the first 141
amino acids of CBFl3 (1-141/GST) retained the ability to
associate with CBFa. Further truncation of the carboxyl
terminus to amino acid 133 (1-133/GST) greatly weakened
association with CBFa, as indicated by the smearing between
the a + ,B and a complexes, whereas deletion of the first 10
amino acids (11-141/GST) abolished all association with
CBFa. The GST domain had a rather dramatic effect on the
mobility of the a + f3 complex (Fig. 4A, second and last lanes).
The CBF, mutant corresponding to the CAex3/M construct
has been previously shown not to associate with CBFa (17).
These CBFa association properties were maintained in
CBFf,-SMMHC deletion mutants. As shown in Fig. 4B,
extracts from cells expressing mutants unable to associate with
CBFa formed only the normal CBF/DNA EMSA complex
(lanes 2-4). Extracts from cells expressing mutants able to
associate with CBFa but unable to multimerize formed larger
complexes (lanes 7, 8), due to the large size of the mutant
proteins relative to the normal CBF subunits. Extracts from
cells expressing mutants able to both associate with CBFa and
form multimers formed the large complex in the gel wells seen
with full-length CBF(3-SMMHC (lanes 6, 9). Extracts from
cells expressing CAC32/M formed a faint EMSA complex in
the gel wells in addition to the normal complex (lane 5).
Multimer Formation by Proteins Expressed in NIH 3T3
Cells. We assessed whether the proteins expressed in NIH 3T3
cells were forming multimers by determining their solubilities
over a range of salt concentrations, as has previously been
done for various myosin heavy chains (27-29). As shown in Fig.
4 C, CBF,B was completely soluble in 3T3 cells at all salt
concentrations. CBFf-SMMHC, however, was relatively in-
soluble, indicating that it is present in the cells predominantly
as multimers. The ,B13 and 1314 antibodies crossreacted with
endogenous murine CBF,B, causing the solubility curve to be
'15% higher than the curve obtained when antibody GPPP
was used for protein detection (data not shown). The SMMHC
tail region alone had the same solubility properties as CBFf,-
SMMHC (data not shown). Mutants with truncated carboxyl
termini were completely soluble (Fig. 4 C, C/MAC68),
whereas mutants with deletions of other regions had the same
solubility as full-length CBF(-SMMHC (Fig. 4C, C/MAI1182).
DISCUSSION
This study demonstrates that the CBFf3-SMMHC chimeric
protein associated with M4Eo acute myeloid leukemia is a
potent transforming agent in 3T3 cells. This transforming
ability depends on regions of the protein necessary for asso-
ciation with CBFa and formation of myosin filaments. These
results provide functional evidence for the central role of this
protein in inv(16) leukemia, which previously has only been
inferred from the presence of the fusion transcripts in patients
(3, 30, 31).
While immunoblots showed that human CBF,3 was ex-
pressed in stably transfected cells, there was no increase in the
intensity of CBF/DNA complexes formed by extracts from
these cells. This result may indicate that the DNA-binding
activity of CBF is limited by the amount of CBFa in the cell.
Cells expressing CBFf-SMMHC, however, showed a dramat-
ically altered CBF/DNA complex. This complex can be
formed by CBFa and CBFf3-SMMHC proteins alone (25) and
is much different than the complex formed by extracts from
NIH 3T3 cells transformed by Ha-ras (22). It therefore appears
to be a specific characteristic of CBF,B-SMMHC expression.
The large size of the complex is most likely due to multimer
Proc. Natl. Acad Sci. USA 92 (1995)
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FIG. 4. (A) EMSA of purified bacterially expressed, truncated
CBF,3 proteins fused to GST. The CBF(3 amino acids fused to GST are
indicated above each lane. The truncated CBF,B/GST proteins were
mixed with purified CBFa and incubated with a probe containing a
high-affinity CBF-binding site. Arrows at left indicate the position of
complexes resulting from DNA binding by CBFa alone (a arrow) or
by CBFa and CBFf3 together (a + 3 arrow). The first lane contains
no CBF3 protein, and the last lane contains full-length CBF,B protein
cleaved from GST. (B) EMSA of nuclear extracts from cells stably
expressing the indicated mutants incubated with a probe containing a
high-affinity CBF-binding site. The first lane has nuclear extracts from
cells expressing insertless vector. Cells expressing C165 and MHCR
constructs had an EMSA complex identical to that seen in cells
transfected with vector alone (data not shown). All of the complexes
detected by EMSA disappeared in the presence of a large excess of
unlabeled probe but not in the presence of a large excess of probe with
a mutated CBF-binding site (data not shown). (C) Solubility curves of
recombinant proteins in NIH 3T3 cells. Proteins were detected by
using antibodies (313 and (314. The bar for each data point represents
the SEM from five different experiments. C/MAC158 had the same
solubility curve as C/MAC68 (data not shown).
formation mediated by the SMMHC carboxyl terminus.
Whether these multimers are typical bipolar myosin filaments
or less ordered protein aggregates is not yet clear.
This study suggests that NIH 3T3 transformation is caused
by multimeric CBFl3-SMMHC/CBFa complexes that retain
the ability to bind CBF-binding sites. These complexes may
interfere with the normal function of CBF in a dominant
negative manner, either by causing the mislocalization of
CBFa within the cell or by binding DNA at CBF sites and
interfering with the adjacent binding of cooperating transcrip-
tion factors (8, 9). This complex may also acquire novel
properties and thereby transform cells through a dominant
positive mechanism.
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